Inflammatory bowel disease

This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...

Cure8 could only read part of this source from eurekalert.org, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...

This study tests whether combining exclusive enteral nutrition with a follow-up fecal microbiome transfer can create a longer-lasting, less inflammatory gut microbiome — which could help maintain remission in Crohn’s...

Access and insurance issues can delay IBD medications and lead patients to skip doses or make financial sacrifices. That can worsen health and daily life, so this affects many people with Crohn’s disease and ulcerative...

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

Cure8 could only read part of this source from thechronicle.com.au, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Diet and lifestyle.

This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Anti-TNF. The original article is from msn.com.

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

A public figure with Crohn’s disease is the subject of a high-profile estate dispute; mentions of his long battle with Crohn’s may be of interest to people who follow celebrities living with IBD or who seek solidarity in...

People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk...

Understanding that low patient activation can reflect poor health literacy helps explain disparities in access, diagnosis delays, and outcomes for children with IBD. Improving communication and education could make care...

Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from msn.com.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Vulvar Crohn’s is an uncommon but real extraintestinal manifestation that can cause painful skin changes and sometimes appears before GI Crohn’s is diagnosed. Knowing about it may speed diagnosis and lead to coordinated...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from firstwordpharma.com.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the full...

The article centers on how Crohn’s affects Black people differently because of access barriers, stigma, and underrepresentation—issues that can influence diagnosis, disease severity, and quality of life.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response...

Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...

This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...

This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from wellandgood.com.

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

Early-stage work on a new bispecific antibody could point to a different immune-regulatory approach for treating inflammatory bowel disease. Patients and clinicians watching IBD drug development may find the mechanism...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

People with IBD — especially men — may have higher long-term risk of ischemic heart disease according to this large observational study. That could influence discussions about cardiovascular risk assessment and...

This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.

Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...

This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...

Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement...

Local support groups can provide practical tips, emotional support, and community connections for people living with Crohn’s disease or ulcerative colitis. This meeting offers both in-person and virtual options, making...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.

Bowel obstruction is a potentially serious complication of Crohn’s disease that may need urgent treatment. The article summarizes common causes (strictures, adhesions, tumors), typical symptoms to watch for, and the...

This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Vedolizumab. The original article is from insights.citeline.com.